Charles River Endosafe Cartridge manufacturing has entered a new automated era, with Charles River Laboratories International, Inc. (NYSE: CRL) confirming on September 8, 2026 that it has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite at its Wilmington, Massachusetts operations. The upgrade marks a significant advancement in bacterial endotoxin testing cartridge production, expanding in-process inspection, strengthening digital traceability, and reinforcing manufacturing controls across the site.
The Charles River Endosafe Cartridge automation initiative is designed to support customer demand that has grown steadily as pharmaceutical, biotechnology and medical device manufacturers rely on rapid, quantitative endotoxin analysis during drug and device release testing. Charles River said the suite consolidates the essential components of endotoxin testing into a single disposable cartridge, enabling real-time, quantitative results without the multi-step handling traditional testing formats require.
“Bringing the automated cartridge manufacturing suite to full operation is an important milestone in our commitment to continuous improvement and operational excellence,” said Daniel Fernandes, Senior Site Director, Microbial Solutions, Charles River. He added that automation and advanced inspection technologies give the company greater visibility into manufacturing performance while strengthening process control and traceability.
The automated suite is expected to reach full operational capacity in the third quarter of 2026, representing what Charles River describes as a major investment in advanced manufacturing technology. The company positioned the upgrade as a foundation for both near-term quality improvements and longer-term scalability as demand for its Endosafe testing platform continues to expand across global markets.
Charles River Endosafe Cartridge Automation Suite Reaches Full Operational Capacity
The Charles River Endosafe Cartridge suite became fully operational in July 2026, giving the company roughly two months of production data before this week’s announcement. Charles River has used that window to benchmark automated output against its prior manual cartridge production process, tracking scrap rates, invalid cartridge rates, production capacity and labor productivity as core performance indicators.
Reaching full operational capacity in the third quarter of 2026 is described by the company as a milestone in a broader modernization strategy for its Microbial Solutions business, which supplies Endosafe cartridges used in bacterial endotoxin testing across the pharmaceutical and medical device industries. The Endosafe platform is built around Limulus Amebocyte Lysate, or LAL, chemistry, as well as Charles River’s recombinant Trillium™ cartridge line, both of which are manufactured on the newly automated line.
By formalizing the transition from manual to automated cartridge assembly, Charles River is aligning its own internal quality systems with the same rigor its customers apply when using Endosafe cartridges for regulatory release testing, a dynamic the company frames as central to its broader manufacturing strategy.
Charles River Endosafe Cartridge Production Delivers Measurable Quality Gains
Since becoming fully operational in July 2026, the Charles River Endosafe Cartridge line has delivered measurable improvements across quality, efficiency and operational performance compared with manual production, according to the company’s disclosed figures.
| Metric | Automated Suite Result | Comparison Basis |
|---|---|---|
| Scrap rate | 2% reduction | vs. manual cartridge production |
| Invalid cartridge rate | 13% reduction | vs. manual cartridge production |
| Production capacity | 14% increase | Across Trillium and LAL cartridges |
| Labor productivity / manufacturing efficiency | 87% improvement | vs. manual cartridge production |
| Full operational date | July 2026 | Company-reported |
| Full operational capacity target | Q3 2026 | Company-reported |
Charles River attributed the scrap rate and invalid cartridge rate improvements directly to tighter process control, noting that reduced waste and improved product consistency were among the earliest measurable benefits of the changeover. The reported 14% increase in production capacity spans both the Trillium and LAL cartridge families, which the company said positions it to meet growing customer demand without a proportional increase in production headcount.
The 87% improvement in labor productivity and manufacturing efficiency stands out as the most significant of the four disclosed metrics. Charles River said the gain enables higher throughput with fewer production resources while reducing the risk of human error, a combination the company links to both cost discipline and quality assurance. Specific dollar figures tied to the automation investment, along with unit-level production volumes, were not disclosed in the announcement.
Inside the Charles River Endosafe Cartridge Automated Inspection Process
A defining feature of the Charles River Endosafe Cartridge automated suite is its ability to inspect every cartridge produced, rather than relying on the sampling-based quality checks common to traditional manufacturing lines. The system performs full inspections across several critical quality parameters before a cartridge is released for distribution.
| Inspection Parameter | Function | Quality Objective |
|---|---|---|
| Cartridge thickness | Dimensional inspection | Structural and performance consistency |
| Reagent fill (via imaging) | Imaging-based fill verification | Accurate reagent dosing |
| Package seal integrity | Automated seal check | Product sterility and shelf stability |
| Digital traceability | Unique cartridge ID assignment | Lifecycle tracking and investigations |
“Automation is helping us do more than improve quality. It allows us to optimize how we deploy our talent,” said Matt Hewitt, Corporate Vice President, Chief Technology Officer Manufacturing, Charles River. He said reducing the manual effort required to manufacture cartridges has allowed the company to redirect skilled employees toward higher-value continuous improvement and growth initiatives.
Charles River also pointed to upstream supply chain changes supporting the automated line, including a switch to automated flat-tray packaging that reduces manual handling and improves raw material consistency. The company said these packaging changes have benefited both its automated and remaining manual production processes, reinforcing quality across its broader Microbial Solutions manufacturing footprint.
Each cartridge produced on the Charles River Endosafe Cartridge line now carries a unique identifier that supports traceability throughout its lifecycle, allowing manufacturing teams to review inspection images, dimensional measurements and packaging results tied to any individual unit. Charles River said this visibility supports faster internal investigations and continuous process optimization.
